Correlations between tumour markers in ascitic fluid and serum were investigated to determine whether ascitic fluid analysis had any diagnostic advantage over serum in 91 adults with ascites (55 malign; 36 benign). Serum and ascitic fluid were analysed for carcinoembryonic antigen (CEA), cancer antigen (CA) 125, CA19.9, CA72.4, CA15.3, a-fetoprotein (AFP) and cytokeratin-19 fragment (CYFRA). The tumour markers were skewed between the groups so were logarithmically transformed. Correlations between serum and ascitic fluid were tested using Pearson's correlation coefficient. Serum and ascitic fluid levels of CEA, CA125, CYFRA and AFP in the malign group were statistically different and CEA, CA19.9, CA5.3, CYFRA and AFP were statistically different in the benign group. For both groups, all tumour markers were highly correlated in serum and ascitic fluid, with the exception of CYFRA in the malign group. These results indicate that, where malignant ascites is suspected, analysing tumour markers in ascitic fluid does not have any advantage over serum analysis.
Introduction
Ascites is fluid accumulation in the peritoneal cavity and it is most commonly caused by liver cirrhosis. 1 Malignancy accounts for approximately 10% of the causes of ascites. 1 Most cancers that occur within the abdomen or pelvis may disseminate into the peritoneum, and metastatic peritoneal tumours are often found on autopsy, being much more common than primary peritoneal tumours: tumours that preferentially invade the peritoneum are adenocarcinomas of the ovary, stomach, colon, pancreas, breast and lung, as well as lymphomas and other sarcomas. 2 Cytology is an important diagnostic tool to confirm diagnosis of ascites, but its sensitivity is only about 50%. 3 There is, therefore, a need for other noninvasive diagnostic techniques to support the ascites diagnosis.
Tumour markers can be used to determine risk, screen for early cancers, confirm diagnosis, predict prognosis or monitor for disease recurrence or progression. 4 Although such markers are conventionally examined in serum samples, they may also be analysed in effusion fluid with the aim of Y Tuzun, Y Ç elik, K Bayan et al. Correlation of tumour markers in ascitic fluid and serum increasing diagnostic performance. 5 -8 Simultaneous measurement of tumour markers in pleural, ascitic effusions and serum has been found to improve diagnostic accuracy. 5, 9 Although there are some published data on the statistical correlation between serum and pleural effusions, 5, 10 to the best of our knowledge there are no data on the statistical correlation between serum and ascitic tumour markers.
The aim of the present study was to investigate correlations of tumour markers in ascitic fluid and serum in order to determine whether examination of these tumour markers in ascitic fluid might improve the diagnostic accuracy of malignant ascites compared with examination of the markers in serum.
Patients and methods

PATIENTS
The study population consisted of consecutive adult patients with ascites admitted to The Dicle University Hospital Gastroenterology and Medical Oncology Department between March 2006 and February 2008. Enrolled patients were divided into two groups: those with malignancy (malign group) and those without malignancy (benign group). Patients were proven to have malignancy by positive ascitic fluid cytological examination and positive histopathological evaluation in specimens obtained by laparoscopy, endoscopy or laparotomy. Patients with malignancy who had received any treatment for their disease were excluded, to avoid the possibility of negative treatment effects. The benign group consisted of patients with liver cirrhosis without any proven malignancy. The study was performed in accordance with the principles of the Declaration of Helsinki and signed informed consent was obtained from all patients prior to inclusion in the study. As this study was performed as part of routine clinical practice, ethics committee approval was not required.
BIOCHEMICAL AND CYTOLOGICAL INVESTIGATIONS
Abdominal paracentesis was performed on all patients. Samples of ascitic fluid were obtained from the left lower abdominal quadrant under aseptic conditions using a 22-gauge needle and were sent for biochemical (including tumour markers) and cytological examination. The tumour markers analysed were carcinoembryonic antigen (CEA), cancer antigen (CA) 125, CA19.9, CA72.4, CA15.3, α-fetoprotein (AFP) and cytokeratin-19 fragment (CYFRA), using an electrochemiluminescence immunoassay (Roche Modular Analytics E170 Cobas; Roche Diagnostics, Mannheim, Germany). Blood samples were also obtained from the patients and processed for biochemical analysis and tumour marker investigation. Routine haematological, biochemical and radiological investigations were performed. Conventional cytological examination of ascitic fluid was performed using haematoxylin and eosin, and Giemsa stains. Analyses were repeated three times before malignancy was excluded. Patients diagnosed with cancer but with negative ascitic cytology were included in the malignant group. Cancer patients with portal hypertension who a serum-ascites albumin concentration gradient (SAAG) > 1.1 g/dl and serum albumin < 3 g/dl were not included in the malignant group.
STATISTICAL ANALYSIS
Distributions of the tumour markers (CEA, CA125, CA19.9, CA72.4, CA15.3, CYFRA and AFP) in serum and in ascitic fluid for the benign and malign groups were skewed. Data transformation can convert a skewed Y Tuzun, Y Ç elik, K Bayan et al.
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distribution into a symmetrical form and logarithmic transformation compresses high values together and stretches smaller values apart and can also be used to stabilize the variation of a sample. 11 Logarithmic transformation was, therefore, applied to the present data and the means and SDs were calculated. Student's t-test for two independent samples was used to compare the concentration means of the tumour markers for the benign and malign groups and correlations were calculated using Pearson correlation coefficient. All statistical tests were two-tailed, with P < 0.05 being the level at which statistical significance was established. All analyses were conducted using the Statistical Package for Social Sciences (SPSS ® version 15.0; SPSS Inc., Chicago, IL, USA).
Results
DEMOGRAPHIC DATA
A total of 91 patients (47 males, 44 females) with ascites were enrolled into the study (55 in the malign group, 36 in the benign group), with mean ± SD ages 59.16 ± 14.99 years and 57.08 ± 15.03 years, respectively (no statistically significant difference in age). The distribution of malignancies was: 16 gastric carcinomas, 10 colon carcinomas, nine malign mesotheliomas, six ovarian cancers, three breast cancers, five pancreas adenocarcinomas, four non-Hodgkin's lymphomas and two adenocarcinomas of primary unknown origin.
LEVELS OF TUMOUR MARKERS
Logaririthmic mean levels of tumour markers in serum and ascitic fluid for the malign and benign groups are summarized in Table 1 . For the malign group, mean levels for CEA, CA125 and CYFRA were significantly higher in ascitic fluid than in serum (P = 0.004, P < 0.000 and P < 0.000, respectively), whereas the mean level for AFP was significantly lower in ascitic fluid compared with serum (P < 0.000). Levels of CA19-9, CA72.4 and CA15.3 for the malign group were not significantly different in serum and ascitic fluid. For the benign group, the mean level of CYFRA was significantly higher in ascitic fluid compared with serum (P < 0.000), whereas levels of CEA, CA19.9, CA15.3 and AFP were significantly lower in ascitic fluid compared with serum (P < 0.000). Levels of CA125 and CA72.4 for the benign group were not significantly different in serum and ascitic fluid.
There were statistically significant differences in the malign group compared with the benign group for levels of CEA in serum (P = 0.009) and ascitic fluid (P = 0.000), CA19.9 in ascitic fluid (P = 0.000), CA72.4 in serum (P = 0.000) and ascitic fluid (P = 0.000), CA15.3 in ascitic fluid (P = 0.000), CYFRA in ascitic fluid (P = 0.000) and AFP in serum (P = 0.000) and ascitic fluid (P = 0.006).
CORRELATION MATRIX
The correlation matrix for the malign group indicated that all tumour markers except for CYFRA were highly correlated in serum and ascitic fluid with correlation coefficients as follows (all P < 0.01): 0.94 for CA72.4, 0.86 for AFP, 0.85 for CA19.9, 0.77 for CA15.3, 0.66 for CEA and 0.61 for CA125 ( Table 2) .
All the tumour markers were also significantly correlated in serum and ascitic fluid in the benign group (Table 3 ). The correlation coefficients were: 0.45 for CA72.4 (P < 0.05), 0.93 for AFP (P < 0.01), 0.62 for CA19.9 (P < 0.01), 0.66 for CA15.3 (P < 0.01), 0.76 for CEA (P < 0.01), 0.54 for CYFRA (P < 0.01) and 0.43 for CA125 (P < 0.01).
Discussion
It is well known that about 80% of cases of Y Tuzun, Y Ç elik, K Bayan et al.
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ascites occur during decompensation of liver cirrhosis, but tumours, which constitute the second most common cause of ascites, account for 10% of cases. 1 Investigations into the diagnostic techniques for suspected malignant ascites have focused on whether laboratory measurements could replace invasive procedures and it was thought that the measurement of tumour markers in serum and effusions might be a solution. 12, 13 However, tumour markers are not specific and several benign diseases, such as renal failure, liver cirrhosis, infections and jaundice, may produce increased levels in serum and secondarily high levels in ascitic and pleural fluid. 14 Several tumour markers in ascitic fluid, for example CEA, CA125, CA19.9 and CYFRA, have been assessed as potential diagnostic tools in malign or benign ascites, especially in situations where cytological examinations are insufficient. 5, 6, 15 In clinical practice, it has been assumed that tumour markers are released from tumour cells that invade the peritoneum and, therefore, it might be assumed that the levels of tumour markers in ascitic fluid could be used for diagnostic purposes. The present study aimed to evaluate this approach by investigating the correlations of tumour markers in ascitic fluid and serum.
In malignant ascites, the results of the correlation matrix showed that all the tumour markers that were investigated, with the exception of CYFRA, were highly correlated in serum and ascitic fluid. This indicates that the examination of tumour markers in ascitic fluid does not provide any advantage in the diagnosis of malignant ascites over the examination of markers in Although mean levels of CEA, CA125 and CYFRA were significantly higher in ascitic fluid than in serum in the malign group, the routine measurement of these markers in ascitic fluid is difficult in clinical practice and, therefore, it would not make diagnostic evaluation more practical. Furthermore, it has been reported that CA125, CYFRA and CEA are produced by normal mesothelial cells, 16 -19 which explains why benign effusions show increased levels. Exceptionally, although CYFRA levels were found to be much higher in ascitic fluid than in serum in the present study and it might be proposed that ascitic fluid CYFRA levels should be determined in ascites, it is difficult to make such a firm statement until further studies are carried out. In fact some studies have concluded that the measurement of ascitic tumour markers does not improve the discriminative ability of malignant effusions. 7, 8, 15, 20 Nevertheless, the present study found that AFP levels were higher in serum than in ascitic fluid and this agrees with the view that AFP levels are always higher in serum than in ascites and are much more sensitive than ascitic cytology in detecting hepatocellular carcinoma. 2 Benign diseases, especially liver cirrhosis, tuberculous peritonitis or nephrotic syndrome have also been the focus for ascitic fluid tumour marker analysis. 16, 21 Falsepositive CA125 results have been found in ascites associated with liver cirrhosis 21 and the causes of an association of tumour markers with liver diseases can vary: increases in serum AFP levels might be associated with liver regeneration, 22 whereas disorders in catabolism and excretion might be associated with increases in CEA or CA19.9 levels. 23, 24 In the patients with benign ascites in the present study, tumour markers were found to be correlated in ascitic fluid and serum. Although they cannot be accepted as being specific in benign diseases, in our opinion CYFRA and CA125 in particular can be expected as the major antigens produced by normal mesothelial cells. No recommendations relating to the use of these markers in benign ascites can, therefore, be made.
Although tumour markers have been reported as useful tools in the differential diagnosis of ascites, 6, 15 the present study found that in cases of suspected malignant ascites, the measurement tumour markers in ascitic fluid does not add any diagnostic advantages over measuring them in serum. For both the malign and benign groups, all tumour markers were highly correlated in serum and ascitic fluid, with the exception of CYFRA in the malign group.
